Supportive Care in Cancer

, Volume 15, Issue 4, pp 441–444 | Cite as

Is there a ceiling effect of transdermal buprenorphine? Preliminary data in cancer patients

  • Sebastiano Mercadante
  • Patrizia Ferrera
  • Patrizia Villari
Short Communication

Abstract

Objective

The aim of this preliminary study was to explore the possibility of using higher doses of transdermal buprenorphine (TD-BUP) than those commonly used and available as manufactured patches, which are based on the assumption that BUP may have a ceiling effect that has never been determined yet.

Materials and methods

Ten patients who were already receiving TD-BUP (70 μg/h, which is about 1.6 mg/day) and were no longer responsive to this dosage were administered higher doses up to a maximum of 140 μg/h within 6 days, when the study was completed.

Results

In six patients, dose increments of TD-BUP were effective, and patients achieved adequate analgesia within 6 days. Four patients discontinued the treatment due to inefficacy of TD-BUP 140 μg/h and were switched to other opioids until achieving stabilization (oxycodone 320 and 400 mg/day, methadone 120 mg/day, transdermal fentanyl 200 μg/h). This group of patients required higher doses than those chosen for TD-BUP, underlying the need to escalate the dose rapidly, a modality not accomplished with transdermal drugs. Adverse effects did not change and were similar to those observed before increasing the dose of TD-BUP. On the basis of these preliminary data, patients requiring doses higher than 70 μg/h of TD-BUP, in the range of 105–140 μg/h, may still have an analgesic benefit without important consequences in terms of adverse effects. It cannot be excluded that even higher doses may be effective, as some patients required rapid titration with higher morphine equivalent doses, and according to the protocol, other opioids were provided to facilitate this process. Further studies should clarify the role and the benefit of TD-BUP in specific clinical circumstances.

Keywords

Cancer pain Transdermal buprenorphine 

References

  1. 1.
    Adriansen H, Mattelaer B, Vanmeenen H (1985) A long-term open, clinical and pharmacokinetic assessment of sublingual buprenorphine in patients suffering from chronic pain. Acta Anaesthesiol Belg 36:33–40Google Scholar
  2. 2.
    Atkinson R, Schofield P, Mellor P (1990) The efficacy in sequential use of buprenorphine and morphine in advanced cancer pain. In: Doyle D (ed) Opioids in the treatment of cancer pain. Royal Society of Medicine, London, pp 81–87Google Scholar
  3. 3.
    Bohme K, Likar R (2003) Efficacy and tolerability of a new opioid analgesic formulation, buprenorphine transdermal therapeutic system (TDS), in the treatment of patients with chronic pain. A randomised double-blind, placebo-controlled study. Pain Clinic 18:193–202CrossRefGoogle Scholar
  4. 4.
    Christoph T, Kogel B, Schiene K, Friderichs E (2005) Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain. Eur J Pharmacol 507:87–98PubMedCrossRefGoogle Scholar
  5. 5.
    Davis M (2005) Buprenorphine in cancer pain. Support Care Cancer 13:878–887PubMedCrossRefGoogle Scholar
  6. 6.
    Hanks GW, De Conno F, Cherny N, Kaldo E, McQuay HJ, Mercadante S, Meynadier J, Poulain P, Ripamonti C, Radbruch L, Roca i casas J, Sawe J, Twycross RG, Ventafridda V (2001) Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 84:587–593PubMedCrossRefGoogle Scholar
  7. 7.
    Kogel B, Christoph T, Strabburger W, Friderichs E (2005) Interaction of mu-opioid receeptor agonists and antagonists with the analgesic effect of buprenorphine in mice. Eur J Pain 9:599–611PubMedCrossRefGoogle Scholar
  8. 8.
    Koppert W, Ihmsen H, Korber N, Wehrfritz A, Sittl R, Schmelz M, Schutter J (2005) Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model. Pain 118:15–22PubMedCrossRefGoogle Scholar
  9. 9.
    Mercadante S, Villari P, Ferrera P, Porzio G, Aielli F, Verna L, Casuccio A (2006) Safety and effectiveness of intravenous morphine for breakthrough pain in patients receiving transdermal buprenorphine. J Pain Symptom Manage 32:175–179PubMedCrossRefGoogle Scholar
  10. 10.
    Sittl R, Griessinger N, Likar R (2003) Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomised, double-blind, placebo-controlled trial. Clin Ther 23:150–168CrossRefGoogle Scholar
  11. 11.
    Schriek P (2004) Treatment of cancer-related pain with transdermal buprenorphine: a report of three cases. Support Care Cancer 12:882–884PubMedCrossRefGoogle Scholar
  12. 12.
    Walsh S, Preston KL, Bigelow GE, Stitzer ML (1995) Acute administration of buprenorphine in humans: partial agonist and blockade effects. J Pharmacol Exp Ther 274:361–372PubMedGoogle Scholar
  13. 13.
    Yassen A, Olofsen E, Romberg R, Sarton E, Danhof M, Dahan A (2006) Mechanism-based pharmacokinetic–pharmacodynamic modeling of the antinociceptive effect of buprenorphine in healthy volunteers. Anesthesiology 104:1232–1242PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Sebastiano Mercadante
    • 1
    • 2
  • Patrizia Ferrera
    • 1
  • Patrizia Villari
    • 1
  1. 1.Anesthesia & Intensive Care Unit and Pain Relief & Palliative Care Unit, La Maddalena Cancer CenterPalermoItaly
  2. 2.Palliative Medicine, University of PalermoPalermoItaly

Personalised recommendations